Figure 4.

(A) Evolution of median CD4⁺ T cells/µL and CI₉₅ in the two groups. (B) Evolution of median CD4⁺/CD8⁺ ratios and CI₉₅ in the two groups. (C) Estimated marginal means of CD4⁺ T cells and CI₉₅ throughout the follow-up adjusted for age, gender, risk for HIV infection, highest viral load before starting antiretroviral treatment, and number of blips during the follow-up. (D) Estimated marginal means of CD4⁺/CD8⁺ ratios and CI₉₅ throughout the follow-up adjusted for age, gender, risk for HIV infection, highest viral load before starting antiretroviral treatment, and number of blips during the follow-up. 3DR, three-drug regimen; 2DR, two-drug regimen.